Subscribe to NRx Newsletter

Home

Hope • Science • Life

We bring
hope to life

People facing life-threatening diseases need the possibility of tomorrow. We bring them hope through life-saving medicines, today.

We bring
hope to life

People facing life-threatening diseases need the possibility of tomorrow. We bring them hope through life-saving medicines, today.

Discover Our Pipeline

We go after the most critical medical conditions and unmet needs.

Discover Our Pipeline

We go after the most critical medical conditions and unmet needs.

Resources & Patient Stories

We create innovative, life-saving treatments and bring hope to those facing life-altering conditions with no approved disease-modifying therapies or cures.

Resources & Patient Stories

We create innovative, life-saving treatments and bring hope to those facing life-altering conditions with no approved disease-modifying therapies or cures.

H.C. Wainwright & Co. Global Investment Conference

The H.C. Wainwright & Co. Global Investment Conference took place on May 24, 2022 and featured interim Chief Executive Officer, Robert Besthof, and other executive leaders presenting a virtual update to the company’s business via webcast.

Aviptadil Right to Try

Right to Try

Aviptadil Right to Try – for US-licensed physicians who wish to obtain Aviptadil under Right to Try laws for Critical COVID-19 patients with no therapeutic alternative.

Latest news

We go after the most critical medical conditions and unmet needs.

We audaciously work to research, develop, and scale solutions to help people that desperately need them.

We accomplish our mission by directing deep scientific and clinical expertise towards innovative clinical development protocol, while simultaneously investing in scalability and stability to ensure our medicines are easily accessible to people around the world.

We leverage proven science and clinical expertise to identify and apply medical solutions as immediately as possible.

Discovery Pipeline

We are advancing the development of multiple new therapeutic candidates in Phase 2 and Phase 3 trials.

Each product in our pipeline has expansive potential beyond their initial indicated targets, and with this, we can save more lives and hope becomes reality for even more people.

Highlights

Today, no medicine is approved to treat patients with bipolar depression suffering suicidal ideation.

NRX-101 is a patented, oral fixed-dose combination of two FDA-approved drugs: D-cycloserine, an NMDA receptor modulator; and Lurasidone, a 5-HT2a receptor antagonist.

NRX-101 An investigational, rapid-onset and sustained treatment for Bipolar Depression in patients with Acute Suicidal Ideation and Behavior.

ZYESAMI® has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA)for the treatment of Critical COVID-19 with respiratory failure, and is now in clinical trials.

ZYESAMI® (Aviptadil) is an investigational medicine for the treatment of Acute Respiratory Failure in patients with Critical COVID-19, and for the prevention of respiratory failure in patients with Severe COVID-19.

ZYESAMI® is a proprietary, shelf-stable formulation of Aviptadil, a synthetic form of human Vasoactive Intestinal Peptide (VIP). VIP is an endogenous substance produced by the body that, among other functions, helps protect cells against inflammatory conditions.

Stories

A COVID-19 Story:

Appreciating the value of a breath

We create innovative, life-saving treatments and bring hope to those facing life-altering conditions with no approved disease-modifying therapies or cures.